Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows
Moderna Inc. (NASDAQ:MRNA) is developing mRNA-1769 as a mpox vaccine for use in adults.
Moderna Inc. (納斯達克:MRNA)正在開發mRNA-1769作爲成人mpox疫苗。
Currently, a Phase 1/2 trial evaluating the safety, tolerability, and immunogenicity of mRNA-1769 in Healthy Participants is underway. The 351-subject trial was started in 2023, and data is anticipated in 2025.
目前，一項評估健康參與者mRNA-1769的安全性、耐受性和免疫原性的1/2期試驗正在進行中。這項351名受試者的試驗於2023年開始，預計數據將在2025年公佈。
In a paper released in Cell, Moderna's mRNA-1769 had been more effective than the Bavarian Nordic A/S (OTC:BVNRY) (OTC:BVNKF) Jynneos vaccine in preventing severe disease and reducing virus levels in monkeys.
在Cell雜誌上發表的一篇文章中，Moderna的mRNA-1769在防止猴子嚴重疾病和降低病毒水平方面比巴伐利亞諾德克公司（場外交易:BVNRY）（場外交易:BVNKF）的Jynneos疫苗更有效。
Also read: Mpox Vaccines: Challenges Persist as Congo Receives First Batch Of Doses Almost 2 Years After It Declared Epidemic.
還閱讀: Mpox疫苗: 剛果在宣佈疫情後近兩年後收到第一批疫苗劑量，挑戰仍然存在。
Jynneos is based on modified vaccinia Ankara (MVA).
Jynneos基於修飾後的天花病毒安卡拉（MVA）。
MVA immunization reduced lesions in challenged non-human primates (NHPs), but most MVA-immunized animals were still classified as experiencing "grave" disease (over 250 lesions) based on WHO lesion number classification. By contrast, none of the mRNA-immunized animals reached the criteria for "severe" disease (over 100 lesions) during the infection period.
MVA免疫可以減少挑戰的非人類靈長類動物的病變，但大多數MVA免疫的動物仍被歸類爲「嚴重」疾病（超過250個病變），根據世衛組織病變數量分類。相比之下，在感染期間，沒有一個mRNA免疫動物符合「嚴重」疾病（100個病變以上）的標準。
While MVA and mRNA-1769 conferred complete protection following lethal mpox infection challenge, mRNA-immunized animals experienced 10-fold fewer lesions, reduced disease duration, and substantial mitigation of circulating and mucosal viremia in the mRNA cohort.
雖然MVA和mRNA-1769在致命的mpox感染挑戰後提供了完全保護，但mRNA免疫動物的病變減少了10倍，疾病持續時間縮短，並且在mRNA隊列中循環和粘膜病毒血症得到了顯著減輕。
The paper highlights that despite the effectiveness of the Jynneos vaccine against mpox, issues in supply, unfavorable reactogenicity, incomplete immunity, and uncertainty of cross-protection to more virulent strains provide critical motivation for the development of a potential new vaccine modality for improved vaccines to cover these gaps.
該論文強調，儘管Jynneos疫苗對付mpox很有效，但供應問題、不利的反應原性、不完全的免疫以及對更具侵略性的菌株的交叉保護的不確定性，爲開發潛在的新疫苗模式提供了關鍵動力，以改善對這些缺口的疫苗。
BioNTech SE (NASDAQ:BNTX) is also developing an mRNA vaccine for mpox, BNT166a, which is also in Phase 1/2 study, with data readout expected in May 2025.
BioNTech SE (納斯達克：BNTX)也正在開發一種mRNA生物-疫苗用於mpox疫苗，BNT166a，也處於1/2期研究階段，預計在2025年5月公佈數據。
Price Action: MRNA stock is down 1.39% at $72.42 at the last check on Friday.
價格走勢：MRNA股票在上週五最後一次檢查時下跌1.39%，至72.42美元。
- Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock.
- 羅賓漢由熱門股票轉變爲市場競爭對手，推出新產品和全球擴張：分析師將股票評級提升。
Photo by Lutsenko_Oleksandr on Shutterstock
Photo by Lutsenko_Oleksandr on shutterstock
